Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme
- PMID: 9816106
Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme
Abstract
We and others have reported that human malignant gliomas demonstrate intratumor heterogeneity in which many regions may be benign; however, the presence of regions of increased malignancy in these same tumors is generally indicative of poor patient prognosis. These data suggested that tumor progression may be a local phenomenon, resulting in regions that progress to a more malignant type prior to the progression of the entire tumor. Implicit in this premise is the idea that molecular markers of tumor progression may be detectable prior to histological evidence of progression. This report details analyses performed on a primary and recurrent tumor obtained from the same patient in which the primary tumor was of a higher histological grade than the recurrent tumor. Results of molecular, cytogenetic, flow cytometric, and histological analyses of the primary tumor were indicative of a grade 4 glioblastoma multiforme. Standard cytogenetic and flow cytometric analyses demonstrated that the cells were near-diploid with a stem line population of 46,XX normal G-banded karyotypes. In contrast, tissue resected from the recurrent tumor 5 months later was histologically less malignant; however, the molecular, cytogenetic, and flow cytometric analyses of this sample demonstrated the presence of specific genetic abnormalities typically found in more malignant tumors. These data demonstrate that specific molecular and/or genetic changes leading to tumor progression may become detectable in a glioma prior to the appearance of histological features of a higher grade tumor.
Similar articles
-
DNA content and chromosomal composition of malignant human gliomas.Neurol Clin. 1985 Nov;3(4):769-84. Neurol Clin. 1985. PMID: 3001489 Review.
-
Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma.Cancer Res. 1995 Apr 1;55(7):1569-77. Cancer Res. 1995. PMID: 7882367
-
Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.Anticancer Res. 2009 Apr;29(4):1255-62. Anticancer Res. 2009. PMID: 19414372
-
Loss of DCC expression and glioma progression.Cancer Res. 1997 Feb 1;57(3):382-6. Cancer Res. 1997. PMID: 9012460
-
Implications of prognostic markers in brain tumors.Clin Lab Med. 1999 Dec;19(4):833-47. Clin Lab Med. 1999. PMID: 10572718 Review.
Cited by
-
LC-ESI-MS/MS-based molecular networking, antioxidant, anti-glioma activity and molecular docking studies of Clematis graveolens.Plant Methods. 2024 Jul 25;20(1):111. doi: 10.1186/s13007-024-01221-3. Plant Methods. 2024. PMID: 39054477 Free PMC article.
-
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.Neoplasia. 2004 Sep-Oct;6(5):636-45. doi: 10.1593/neo.04229. Neoplasia. 2004. PMID: 15548373 Free PMC article.
-
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.J Clin Oncol. 2008 Jun 10;26(17):2839-45. doi: 10.1200/JCO.2007.15.1829. J Clin Oncol. 2008. PMID: 18539962 Free PMC article. Review.
-
Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.Neuro Oncol. 2004 Oct;6(4):290-9. doi: 10.1215/S1152851704000158. Neuro Oncol. 2004. PMID: 15494096 Free PMC article.
-
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.BMC Complement Altern Med. 2006 Aug 16;6:27. doi: 10.1186/1472-6882-6-27. BMC Complement Altern Med. 2006. PMID: 16914050 Free PMC article.